Is interleukin-6 concentration in the dialysate of continuous ambulatory peritoneal dialysis patients a prognostic parameter in peritonitis?
In continuous ambulatory peritoneal dialysis (CAPD) patients, peritonitis is a dangerous complication. Chemical examinations in the dialysate can be successfully used to assess permeability disturbances, hemostatic balance, and (for early detection and follow-up) cellular inflammatory reaction. In 7 CAPD patients (age: 50 +/- 15 years; dialysis duration: 40 +/- 24 months) with peritonitis episodes, and in 17 age-matched CAPD patients (age: 50 +/- 13 years; dialysis duration: 29 +/- 18 months) without peritonitis, we examined daily dialysate cell count (CC) and concentrations of albumin (ALB), immunoglobulin G (IgG), thrombin-antithrombin III complex (TAT), D-dimer (DD), and interleukin-6 (IL-6) after the long dwell (8-10 hours) over an interval of at least 14 days. In CAPD patients with peritonitis episodes, all parameters (CC, ALB, IgG, TAT, DD, IL-6) were significantly increased in the first days [IL-6 mean: 25,190 pg/mL (range: 2560-52,708 pg/mL) vs 66 pg/mL (range: 21-163 pg/mL)]; then, up to day 14 after successful therapy with antibiotics, the levels showed no differences as compared with CAPD patients without peritonitis. In the case of relapse of peritonitis (4 cases), concentration of IL-6 rose again on day 14, 1 day earlier than did the other parameters. Determination of IL-6 in the dialysate is a reliable prognostic parameter for the course of peritonitis (start, end, relapse) in CAPD patients.
Fiedler
R
R
Department of Nephrology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Schneider
I
I
Fischer
K
K
Deuber
H J
HJ
Osten
B
B
D000328:Adult; D000368:Aged; D000418:Albumins / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000032:analysis; D002452:Cell Count; D003430:Cross-Sectional Studies; D015314:Dialysis Solutions / Q000737:chemistry*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D015850:Interleukin-6 / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D011379:Prognosis; D012008:Recurrence
D000418:Albumins; D015415:Biomarkers; D015314:Dialysis Solutions; D005338:Fibrin Fibrinogen Degradation Products; D007074:Immunoglobulin G; D015850:Interleukin-6; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D010447:Peptide Hydrolases